Compare ZKH & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZKH | PRME |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.9M | 536.4M |
| IPO Year | 2022 | 2022 |
| Metric | ZKH | PRME |
|---|---|---|
| Price | $2.94 | $2.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.56 |
| AVG Volume (30 Days) | 71.6K | ★ 3.8M |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | $9.02 | $7.06 |
| Revenue Next Year | $10.41 | $47.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $1.92 | $2.67 |
| 52 Week High | $3.90 | $6.94 |
| Indicator | ZKH | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 40.20 |
| Support Level | $2.88 | $2.68 |
| Resistance Level | $2.97 | $3.60 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 84.31 | 15.00 |
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. Majority of the revenues are derived from the PRC.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.